Patents Examined by Dong Jiang
  • Patent number: 9556276
    Abstract: The invention provides an anti-human IL-23R antibody having excellent activity and/or cross-reactivity compared to conventional IL-23R antibodies and methods of using the same for treating or preventing various diseases in which human IL-23R is involved in the pathogenesis of the diseases.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: January 31, 2017
    Assignee: Astellas Pharma Inc.
    Inventors: Makoto Ohori, Takanori Sasaki, Hiromu Sato, Katsunari Taguchi
  • Patent number: 9523073
    Abstract: A naturally-occurring soluble truncated IL-23R? protein (i.e., ?9 IL-23R?) is shown to be present in a biological sample and can serve as a diagnostic tool for autoimmune diseases. There is provided an enzyme-linked immunosorbent assay (ELISA) and test kit for the serological detection of the soluble truncated form of IL-23R? protein. More particularly, antibody-sandwich ELISA method and kits for ?9 IL-23R? as an antigen were developed to detect ?9 IL-23R? levels in biological samples from a mammal and a human patient and are used as a diagnostic index. The present disclosed ELISA has utility as a diagnostic tool to detect Crohn's disease in patients using EDTA-plasma.
    Type: Grant
    Filed: March 31, 2011
    Date of Patent: December 20, 2016
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Grant Gallagher, Raymond Yu, Joyce Eskdale, Jonathan Brazaitis
  • Patent number: 9512217
    Abstract: The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: December 6, 2016
    Assignee: GENENTECH, INC.
    Inventors: Yongmei Chen, Yan (Helen) Hu, Wenjun Ouyang, Scott Stawicki, Yan Wu
  • Patent number: 9512218
    Abstract: Alleviating neural injury, such as spinal cord injury, in a subject (e.g., a human subject) in need of the treatment using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.
    Type: Grant
    Filed: June 17, 2014
    Date of Patent: December 6, 2016
    Assignee: National Cheng Kung University
    Inventors: Ming-Shi Chang, I-Ming Jou
  • Patent number: 9493533
    Abstract: The present invention relates to the identification of an epitope in human Interleukin-15 (IL-15) that is responsible for binding to the interleukin-15 receptor ?-chain. Two IL-15 regions are involved in the formation of this epitope: the first region (44LLELQVISL52, peptide 1) corresponds to a sequence located in the B helix and the second (64ENLII68, peptide 2 or 64ENLIIL69, peptide 2a) to a sequence located in helix C. Muteins displaying agonist or antagonist properties are described, and may be useful as therapeutic agents.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: November 15, 2016
    Inventors: Jérôme Bernard, Ariane Plet, Yannick Jacques, Catherine Harb, Agnès Quemener, Erwan Mortier
  • Patent number: 9487590
    Abstract: The invention relates generally to activatable antibodies that include a masking moiety (MM), a cleavable moiety (CM), and an antibody (AB) that specifically binds to interleukin-6 receptor (IL-6R), and to methods of making and using these anti-IL-6R activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: November 8, 2016
    Inventors: James William West, Jason Gary Sagert, Daniel Robert Hostetter, Stephen James Moore, Margaret Thy Luu Nguyen, Olga Vasiljeva, Jeanne Grace Flandez
  • Patent number: 9475873
    Abstract: This invention provides fully human monoclonal antibodies that recognize IL-17F and/or the heterodimeric IL-17A/IL-17F complex, but do not recognize IL-17A. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: October 25, 2016
    Assignee: NOVIMMUNE SA
    Inventors: Krzysztof Masternak, Francois Rousseau
  • Patent number: 9475872
    Abstract: Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human Auto-Immunosome and corresponding monoclonal antibody reservoir are provided. In addition, pharmaceutical compositions, kits and methods for use in diagnosis and therapy of are described.
    Type: Grant
    Filed: January 2, 2013
    Date of Patent: October 25, 2016
    Assignee: ImmunoQure AG
    Inventors: Adrian Hayday, Kai Krohn, Annamari Ranki, Part Peterson, Kai Kisand, Edward Stuart, Annalisa MacAgno, Shimobi Onuoha
  • Patent number: 9464134
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: October 11, 2016
    Assignee: ZYMOGENETICS, INC.
    Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, Robert Mabry, Stephen R. Jaspers, Monica J. Huber
  • Patent number: 9416183
    Abstract: The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: August 16, 2016
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • Patent number: 9416168
    Abstract: Provided are engineered soluble hIL-17RA receptors with high affinity to hIL-17 that inhibit downstream IL17A induced signaling events in cells. Also provided are methods of inhibiting hIL-17A induced secretion of CXCL1 and/or IL-6 in cells, as well as methods of treating inflammation and/or inflammatory disorders in a subject.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: August 16, 2016
    Assignee: The National Institute for Biotechnology in the Negev, Ltd
    Inventors: Amir Aharoni, Marianna Zaretzky
  • Patent number: 9403871
    Abstract: The invention relates to an in vitro method for prognosis, diagnosis or determination of the evolution of a condition involving an altered production of Basic Proline-rich Lacrimal Protein (BPLP) or of any of its maturation products, by detecting, or quantifying in a biological sample of a test subject, a BPLP protein or a maturation product thereof, and comparing the production of BPLP protein or maturation product with the production of the same in a biological sample of a control subject.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: August 2, 2016
    Inventors: Catherine Rougeot, Jean-Francois Huaulme, Marie-Noelle Ungeheuer, Anne Wisner, Evelyne Dufour
  • Patent number: 9394362
    Abstract: The invention relates to engineered, humanized antibodies that have high binding affinity for and neutralize human IL-21, methods of using the antibodies to treat conditions in which antagonism or neutralization of the effects of IL-21 is warranted, such as autoimmune conditions, compositions and methods for recombinantly producing the antibodies, and pharmaceutical compositions comprising the antibodies.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: July 19, 2016
    Assignee: Eli Lilly and Company
    Inventors: Julian Davies, Fabio Magrini, Andrea Paula Martin, Neelufar Mozaffarian, Chetankumar N. Patel, Oliver Schroeder
  • Patent number: 9376491
    Abstract: The present invention provides stabilized pharmaceutical formulations for anti-IL-17 antibodies, comprising e.g. citrate, sodium chloride and polysorbate-80 at pH 5.7. These stabilized anti-IL-17 antibody pharmaceutical formulations can be used to treat rheumatoid arthritis, psoriasis, ankylosing spondilitis, psoriatic arthritis or multiple myeloma.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: June 28, 2016
    Assignee: Eli Lilly and Company
    Inventors: Vincent John Corvari, Barbara Ann Williams, Patrick Daniel Donovan, Aaron Paul Markham
  • Patent number: 9375465
    Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: June 28, 2016
    Assignees: Emory University, Children's Healthcare of Atlanta, Inc.
    Inventors: Jacques Galipeau, Hsiang-Chuan Hsieh
  • Patent number: 9376477
    Abstract: The present invention relates to new IL-17 inhibiting polypeptides, corresponding fusion proteins, compositions and medical uses thereof.
    Type: Grant
    Filed: August 24, 2010
    Date of Patent: June 28, 2016
    Assignee: Covagen AG
    Inventors: Dragan Grabulovski, Michela Silacci Melkko, Frédéric Mourlane, Simon Sebastian Brack, Julian Bertschinger, Nadja Baenziger, Sarah Batey
  • Patent number: 9353180
    Abstract: The invention relates to a method for the treatment of an inflammatory disease in a subject suffering from the inflammatory disease, the method comprising the administration to said subject of a compound neutralizing GM-CSF; and a compound neutralizing IL-17.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: May 31, 2016
    Inventor: Christine Plater-Zyberk
  • Patent number: 9266937
    Abstract: Disclosed herein are novel proteins that have reduced binding to the interleukin-7 receptor, compositions containing such proteins, and methods of using the same.
    Type: Grant
    Filed: December 9, 2011
    Date of Patent: February 23, 2016
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventor: Annette Khaled
  • Patent number: 9127057
    Abstract: The present disclosure provides an isolated or recombinant IL-23-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain specifically binds to IL-23 but does not significantly bind to an IL-12p40 subunit and does not significantly bind to an IL-23p19 subunit when they are not components of IL-23. The present disclosure also provides uses of the IL-23-binding protein.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: September 8, 2015
    Assignee: Teva Pharmaceuticals Ausralia Pty Ltd
    Inventors: Adam William Clarke, Anthony G. Doyle, Matthew Pollard, Stephen Tran
  • Patent number: 9127066
    Abstract: Treating a disorder (e.g., osteoporosis, renal failure, or diabetic nephropathy) associated with a signaling pathway mediated by IL-20 receptor with an agent that suppresses IL-20 receptor activity, e.g., an antibody that neutralizes IL-20 receptor via binding to IL-20R1, an antisense nucleic acid that suppresses expression of IL-20R1, a small molecule that inhibits IL-20 receptor activity, or a dominant negative mutant of IL-19, IL-20, or IL-24.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: September 8, 2015
    Assignee: National Cheng Kung University
    Inventor: Ming-Shi Chang